title: [Comparison of benefits to non-dialysis CKD patients between darbepoetin alpha and epoetin beta pegol].
abstract: BACKGROUND
  Erythropoiesis-stimulating agents (ESAs) are the mainstay of treatment for renal anemia in chronic kidney disease (CKD) patients. However, the difference in hematopoietic effect between darbepoetin alfa (DA) and continuous erythropoiesis receptor activator (CERA) has remained unclear in non-dialysis CKD patients. Another purpose of this study was to analyze the red blood cells indices under treatment with these two ESAs in ESA-naïve CKD patients.
  
  
  METHODS
  This study was designed as a multicenter retrospective observational investigation, and included 61 patients receiving DA (group DA) and 36 patients receiving CERA (group CERA) for at least six months. Relative effect of these ESAs was determined by comparing means of the individual monthly average of the area under the curve above the initial level of hemoglobin (Hb), hematocrit (Hct), and red blood cell count (RBC) with the trapezoidal rule, which are maintenance ratios. Serial changes in mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were also evaluated.
  
  
  RESULTS
  No differences were found in the mean ratios of Hb, Hct, and RBC, and maintenance ratios of these parameters. The ratio of MCH in group CERA was decreased compared with that in group DA. Subsequent decrease in MCV was also remarkable in group CERA.
  
  
  CONCLUSIONS
  It is speculated that iron demand increased during the administration of CERA, which was suggested by changes in the red cell indices. Reticulocyte indices and iron-related parameters could provide a more detailed explanation and the significance of iron supplementation during administration of CERA should be clarified when compared with other types of ESA.
authors.forename: Chiharu
authors.initials: C
authors.lastname: Ito
authors.forename: Tetsu
authors.initials: T
authors.lastname: Akimoto
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Morishita
authors.forename: Hisashi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Manabu
authors.initials: M
authors.lastname: Ogura
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Atsushi
authors.initials: A
authors.lastname: Miki
authors.forename: Sumiko
authors.initials: S
authors.lastname: Homma
authors.forename: Eiji
authors.initials: E
authors.lastname: Kusano
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Asano
authors.forename: Daisuke
authors.initials: D
authors.lastname: Nagata
mesh_terms: D000368:Aged; D000740:Anemia / Q000209:etiology; D000068256:Darbepoetin alfa / Q000627:therapeutic use*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D000068256:Darbepoetin alfa